The National Company Law Tribunal (NCLT), Cuttack Bench, has permitted the rectification of a procedural defect in ongoing legal proceedings involving max healthcare institute and its subsidiary, Kalinga Hospital Ltd (KHL). The tribunal’s order, received by the company on August 7, 2026, allows the opposing party to file an additional affidavit to correct an error in a Postal Ballot Notice annexed to their interlocutory petition. This development ensures the continuation of the case, which centers on petitions filed by the legal representatives of BRS Capital Two Pte. Limited against KHL, the other shareholder from whom Max Healthcare acquired a majority equity stake, and the company itself. The next hearing is scheduled for August 19, 2026.

Procedural Developments

The matter was heard on August 4, 2026, at 10:30 am IST. During the hearing, Max Healthcare Institute Ltd and other respondents raised objections regarding the maintainability of the interlocutory petition. The core objection cited an incorrect Postal Ballot Notice attached to the application filed by the legal representatives of BRS Capital Two Pte. Limited.

The NCLT observed that the identified defect was procedural in nature. In the interest of justice and consistent with the principles of natural justice, the tribunal permitted the opposite party to rectify the defect by filing an additional affidavit. Consequently, the interlocutory petition will be heard alongside the main Company Petition at the next scheduled date.

Timeline of Proceedings

Regulatory Disclosure

This disclosure is made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company stated that there is no change in the status of any settlement, as no settlement has occurred. The litigation does not involve key management personnel, promoters, or the ultimate person in control in a manner requiring specific disclosure under those categories. The full details are hosted on the company’s website.

What the Numbers Show

While no financial figures are disclosed in this specific regulatory filing, the continuation of litigation with BRS Capital Two Pte. Limited represents a potential contingent liability for Max Healthcare Institute Ltd. The outcome of the main Company Petition, now proceeding alongside the rectified interlocutory petition, could impact the company’s financial position or strategic control over Kalinga Hospital Ltd. Investors should monitor subsequent filings for updates on the final adjudication of the main petition.

Max Healthcare Institute shareholders approved a final dividend of ₹2 per equity share, authorized the relocation of the company’s registered office from Maharashtra to Haryana, and re-appointed Anil Kumar Bhatnagar as a director during its 25th Annual General Meeting (AGM) held on July 30, 2026. The company filed the minutes of the meeting with stock exchanges on August 6, 2026, confirming that all ordinary and special resolutions were passed with requisite majorities. The approval of the office shift aligns the legal registered address with the operational headquarters in New Delhi, while the dividend declaration reflects sustained cash generation despite significant capital expenditure on hospital expansions.

The meeting was chaired by Abhay Soi, Chairman and Managing Director, who highlighted operational progress in FY26, including capacity expansions in Mohali, Mumbai, and Delhi. He noted the recent acquisition of a 58.28% stake in Kalinga Hospital Limited, now Max Super Speciality Hospital, Bhubaneswar, which strengthens the company’s presence in eastern India. Soi emphasized strategic investments in robotic-assisted surgery, AI-driven clinical workflows, and renewable energy infrastructure as key drivers of long-term value creation. He also highlighted the company's inclusion in the NIFTY 50 Index as a testament to investor confidence.

Voting Results Summary

Shareholders transacted both ordinary and special business items. The following table summarizes the voting outcomes for key resolutions:

Governance and Compliance

Dhiraj Aroraa, Executive Vice President - Company Secretary and Compliance Officer, confirmed that the company complied with all statutory provisions during FY26. He stated that there were no qualifications or adverse remarks in the Statutory Auditor’s Report issued by S.R. Batliboi & Co. LLP or the Secretarial Auditor’s Report issued by DPV & Associates LLP. Chandra Wadhwa & Co. served as the Cost Auditors.

A quorum of 160 members was present via video conference. The Audit Committee, Nomination and Remuneration Committee, and Stakeholders Relationship Committee chairs attended to address shareholder queries. Voting was conducted through MUFG Intime India Private Limited using remote e-voting and InstaVote platforms, with Devesh Kumar Vasisht of DPV & Associates LLP acting as Scrutinizer. The cut-off date for voting eligibility was July 23, 2026, with a total of 234,355 shareholders on record.

Strategic Outlook and Capital Allocation

During the Q&A session, management addressed shareholder concerns regarding leverage and expansion. Yogesh Kumar Sareen, Group Director & Chief Financial Officer, clarified that while loans have increased to fund capacity creation, the company generated free cash flow of around ₹5,500 crore over the last four years. Approximately ₹1,400 crore in new borrowings over the past three years has been deployed for acquisitions and adding around 1,250 beds. Sareen noted that the current net debt-to-EBITDA ratio is less than one, well below the corporate sector average of four times.

Abhay Soi added that the company intends to expand bed capacity from approximately 6,000 to nearly 10,000 by FY30. He stated that the company plans to take leverage up to 2.5 times net debt-to-EBITDA, citing a return on capital employed (ROCE) of northwards of 20-25% against borrowing costs of 7.5% to 8%. Soi dismissed proposals for stock splits or bonus issues, arguing they do not enhance shareholder value given adequate liquidity.

What the Numbers Show

The declaration of a ₹2 final dividend per equity share, representing 20% of the face value, signals continued cash generation despite significant capital expenditure on hospital expansions and acquisitions. The simultaneous approval of the registered office shift to Haryana suggests a strategic alignment with the company’s operational headquarters in New Delhi, potentially streamlining corporate governance and administrative efficiency. The high approval rates for director re-appointments, despite some dissent from institutional investors, indicate overall trust in the board’s leadership.